Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

33.10 +0.88 (+2.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 378,293
Open 32.59
Bid (Size) 33.01 (18)
Ask (Size) 33.07 (1)
Prev. Close 32.22
Today's Range 32.59 - 33.51
52wk Range 18.91 - 44.34
Shares Outstanding 956,637,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in Investor Conferences in September 2025
From Zai Lab Limited
Via Business Wire

Performance

YTD
+33.4%
+33.4%
1 Month
-13.0%
-13.0%
3 Month
+6.1%
+6.1%
6 Month
+4.3%
+4.3%
1 Year
+71.1%
+71.1%

More News

Read More
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
From Zai Lab Limited
Via Business Wire
Earnings Scheduled For August 7, 2025
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
Zai Lab Establishes Oncology Scientific Advisory Board
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
From Zai Lab Limited
Via Business Wire
Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects
Via Benzinga
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
From Zai Lab Limited
Via Business Wire
ZAI LAB LTD-ADR (NASDAQ:ZLAB) – A High-Growth Biotech Stock Meeting Minervini’s Criteria
Via Chartmill
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
From Zai Lab Limited
Via Business Wire
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
Via Benzinga
Guidewire Software Posts Upbeat Q3 Results, Joins Yext, REV Group And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Wednesday's session: gap up and gap down stocks
Via Chartmill
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
Via Benzinga
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
From Zai Lab Limited
Via Business Wire
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in Investor Conferences in June 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
From Zai Lab Limited
Via Business Wire
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
From Zai Lab Limited
Via Business Wire
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
From Zai Lab Limited
Via Business Wire

Frequently Asked Questions

Is Zai Lab Limited - American Depositary Shares publicly traded?
Yes, Zai Lab Limited - American Depositary Shares is publicly traded.
What exchange does Zai Lab Limited - American Depositary Shares trade on?
Zai Lab Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Zai Lab Limited - American Depositary Shares?
The ticker symbol for Zai Lab Limited - American Depositary Shares is ZLAB on the Nasdaq Stock Market
What is the current price of Zai Lab Limited - American Depositary Shares?
The current price of Zai Lab Limited - American Depositary Shares is 33.10
When was Zai Lab Limited - American Depositary Shares last traded?
The last trade of Zai Lab Limited - American Depositary Shares was at 08/29/25 04:00 PM ET
What is the market capitalization of Zai Lab Limited - American Depositary Shares?
The market capitalization of Zai Lab Limited - American Depositary Shares is 31.66B
How many shares of Zai Lab Limited - American Depositary Shares are outstanding?
Zai Lab Limited - American Depositary Shares has 32B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.